Shares of Advaxis Inc. (NASDAQ:ADXS) traded up 1.9% during mid-day trading on Tuesday . The company traded as high as $10.80 and last traded at $10.61, with a volume of 326,539 shares traded. The stock had previously closed at $10.41.

A number of equities analysts have commented on ADXS shares. Jefferies Group reaffirmed a “buy” rating on shares of Advaxis in a report on Thursday, August 4th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Advaxis in a report on Friday, August 5th. Barclays PLC lifted their price objective on shares of Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, August 3rd. Finally, FBR & Co reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Advaxis in a report on Thursday, July 7th. Five analysts have rated the stock with a buy rating, Advaxis presently has a consensus rating of “Buy” and a consensus price target of $24.60.

The stock’s market capitalization is $420.75 million. The stock’s 50-day moving average is $12.42 and its 200 day moving average is $9.48.

In other Advaxis news, Director Richard J. Berman sold 18,000 shares of the company’s stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $15.21, for a total transaction of $273,780.00. Following the completion of the sale, the director now owns 66,430 shares of the company’s stock, valued at $1,010,400.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Sidransky sold 22,808 shares of the company’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $15.01, for a total value of $342,348.08. Following the sale, the director now directly owns 91,759 shares of the company’s stock, valued at approximately $1,377,302.59. The disclosure for this sale can be found here. Company insiders own 4.56% of the company’s stock.

A number of large investors have recently made changes to their positions in ADXS. Sarissa Capital Management LP bought a new stake in shares of Advaxis during the second quarter worth about $4,853,000. Marshall Wace LLP bought a new stake in shares of Advaxis during the second quarter worth about $2,213,000. Parametric Portfolio Associates LLC raised its position in shares of Advaxis by 163.9% in the second quarter. Parametric Portfolio Associates LLC now owns 62,424 shares of the biotechnology company’s stock worth $505,000 after buying an additional 38,769 shares during the period. Allianz Asset Management AG raised its position in shares of Advaxis by 60.5% in the second quarter. Allianz Asset Management AG now owns 185,813 shares of the biotechnology company’s stock worth $1,503,000 after buying an additional 70,045 shares during the period. Finally, Laurion Capital Management LP acquired a new position in shares of Advaxis during the second quarter worth approximately $229,000. 55.86% of the stock is owned by hedge funds and other institutional investors.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

5 Day Chart for NASDAQ:ADXS

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.